转位蛋白及其配体在神经精神疾病中作用
Study on TSPO and Ligand in the Psychiatry and Neurology Disease
DOI: 10.12677/IJPN.2019.82002, PDF,    科研立项经费支持
作者: 郑 培, 吴 伟, 万亚会, 高 微, 周凯丽, 薛 蓉*：天津医科大学总医院神经内科，天津
关键词: 转位蛋白；配体；神经影像；神经精神疾病； TSPO； Ligand； Neuroimaging； Psychiatry and Neu-rology Disease
摘要: 转位蛋白(translocator protein, TSPO)是苯二氮卓类药物外周组织结合位点，又称外周型苯二氮卓受体(peripheral benzodiazepine receptor, PBR)。随着研究的深入，将PBR第一亚单位(即位于线粒体外膜的异喹啉结合点地西泮结合抑制物)重新命名为18kDa转位蛋白。TSPO及其配体在疾病中的重要作用成为近几年研究的热点。研究显示TSPO具有广泛的生理调节功能，参与了卒中、神经退行性病变、神经免疫病及神经精神疾病等多种疾病的发生发展，其配体作为生物标记物和治疗目标，在影像成像及炎症在体监测中扮演着重要的角色。然而，TSPO在神经系统疾病中精确作用仍然是个迷。本文将对TSPO及其配体在中枢神经系统中作用的最新研究进行综述。
Abstract: TSPO is the peripheral tissue binding site of benzodiazepine drugs, also known as peripheral benzodiazepine receptor (PBR). With the further research, the first subunit of PBR (i.e. the isoquinoline binding site of diazepam binding inhibitor located in the outer membrane of mitochondria) was renamed as 18kDa translocation protein. The important role of TSPO and its ligands in diseases has become a hotspot in recent years. Studies have shown that TSPO has a wide range of physiological regulation functions, and is involved in the occurrence and development of stroke, neurodegenerative diseases, neuroimmune diseases, neuropsychiatric diseases and other diseases. As biomarkers and treatment targets, its ligands play an important role in imaging and inflammation monitoring. However, the precise role of TSPO in neurological disorders remains a mystery. This article will review the latest research on the role of TSPO and its ligands in the central nervous system.
文章引用：郑培, 吴伟, 万亚会, 高微, 周凯丽, 薛蓉. 转位蛋白及其配体在神经精神疾病中作用[J]. 国际神经精神科学杂志, 2019, 8(2): 7-12. https://doi.org/10.12677/IJPN.2019.82002

参考文献

[1] Li, F., Liu, J., Liu, N., Kuhn, L.A., Garavito, R.M. and Ferguson-Miller, S. (2016) Translocator Protein 18 kDa (TSPO): An Old Protein with New Functions? Biochemistry, 55, 2821-2831. [Google Scholar] [CrossRef] [PubMed]
[2] Batarseh, A. and Papadopdulos, V. (2010) Regulation of Translocator Protein 18 kDa (TSPO) Expression in Health and Disease States. Molecular and Cellular Endocrinology, 327, 1-12. [Google Scholar] [CrossRef] [PubMed]
[3] Morin, D., Musman, J., Pons, S., Berdeaux, A. and Ghaleh, B. (2016) Mitochondrial Translocator Protein (TSPO): From Physiology to Cardioprotection. Biochemical Pharmacology, 105, 1-13. [Google Scholar] [CrossRef] [PubMed]
[4] Olga, V.C. and Wenbin, D. (2016) Mitochondrial Translocator Protein (TSPO), Astrocytes and neuroinflammation. Neural Regeneration Research, 11, 1056-1057. [Google Scholar] [CrossRef] [PubMed]
[5] Zhan, A.H., Tu, L.N., Mukai, C., Sirivelu, M.P., Pillai, V.V., Morohaku, K., Cohen, R. and Selvaraj, V. (2016) Mitochondrial Translocator Protein (TSPO) Function Is Not Essential for Heme Biosynthesis. The Journal of Biological Chemistry, 291, 1591-1603. [Google Scholar] [CrossRef] 
[6] Hamelin, L., Lagarde, J., Dorothee, G., et al. (2018) Distinct Dynamic Profiles of Microglial Activation Are Associated with Progression of Alzheimer’s Disease. Brain, 141, 1855-1870. [Google Scholar] [CrossRef] [PubMed]
[7] Jin, G.-L., He, S.-D., Lin, S.-M., et al. (2018) Koumine Attenuates Neuroglia Activation and Inflammatory Response to Neuropathic Pain. Neural Plasticity, 5, Article ID: 9347696. [Google Scholar] [CrossRef] [PubMed]
[8] Zeng, J., Guareschi, R., Damre, M., et al. (2018) Structural Prediction of the Dimeric Form of the Mammalian Translocator Membrane Protein TSPO: A Key Target for Brain Diagnostics. International Journal of Molecular Sciences, 19, 2588. [Google Scholar] [CrossRef] [PubMed]
[9] Coste, B., Dapozzo, E., Giacomelli, C., et al. (2016) TSPO Ligand Residence Time: A New Parameter to Predict Compound Neurosteroidogenic Efficacy. Scientific Reports, 6, Article No. 18164. [Google Scholar] [CrossRef] [PubMed]
[10] Verleye, M., Dumas, S., Heulard, I., et al. (2011) Differential Effects of Etifoxine on Anxiety-Like Behavior and Convulsions in BALB/cByJ and C57BL/6J Mice: Any Relation to Overexpression of Central GABAA Receptor Beta2 Subunits? European Neuropsychopharmacology, 21, 457-470. [Google Scholar] [CrossRef] [PubMed]
[11] Filiou, M.D., Banati, R.B. and Graeber, M.B. (2017) The 18-kDa Translocator Protein as a CNS Drug Target: Finding Our Way Through the Neuroinflammation Fog. CNS Neurological Disorders Drug Targets, 16, 990-999. [Google Scholar] [CrossRef] [PubMed]
[12] Bonsack, F., Alleyne, C.H. and Sukumar, S. (2016) Augmented Expression of TSPO after Intracerebral Hemorrhage: A Role in Inflammation? Journal of Neuroinflammation, 13, 151. [Google Scholar] [CrossRef] [PubMed]
[13] Veiga, S., Azcoitia, I. and Garcia, L.M. (2005) Ro5-4864, a Peripheral Benzodiazepine Receptor Ligand, Reduces Reactive Gliosis and Protects Hippocampal Hilar Neurons from Kainic Acid Excitotoxicity. Journal of Neuroscience Research, 80, 129-137. [Google Scholar] [CrossRef] [PubMed]
[14] Leaver, K.R., Reynolds, A., Bodard, S., Guilloteau, D., Chalon, S. and Kassiou, M. (2012) Effects of Translocator Protein (18 kDa) Ligands on Microglial Activation and Neuronal Death in the Quinolinic-Acid-Injected Rat Striatum. ACS Chemical Neuroscience, 3, 114-119. [Google Scholar] [CrossRef] [PubMed]
[15] Gong, J., Szegő, É.M., Leonov, A., et al. (2019) Translocator Protein Ligand Protects against Neurodegeneration in the MPTP Mouse Model of Parkinsonism. Journal of Neuroscience, 2, 2070-2018. [Google Scholar] [CrossRef] 
[16] Lenglet, T., Lacomblez, L., Abitbol, J.L., et al. (2014) A Phase II-III Trial of Olesoxime in Subjects with Amyotrophic Lateral Sclerosis. European Journal of Neurology, 21, 529-536. [Google Scholar] [CrossRef] [PubMed]
[17] Kapanadze, T., Bankstahl, J.P., Wittneben, A., et al. (2019) Multimodal and Multiscale Analysis Reveals Distinct Vascular, Metabolic and Inflammatory Components of the Tissue Response to Limb Ischemia. Theranostics, 9, 152-166. [Google Scholar] [CrossRef] [PubMed]
[18] Locci, A. and Pinna, G. (2017) Neurosteroid Biosynthesis Down-Regulation and Changes in GABAA Receptor Subunit Composition: A Biomarker Axis in Stress-Induced Cognitive and Emotional Impairment. British Journal of Pharmacology, 174, 3226-3241. [Google Scholar] [CrossRef] [PubMed]
[19] Nothdurfter, C., Baghai, T.C., Schüle, C. and Rupprecht, R. (2012) Translocator Protein (18 kDa) (TSPO) as a Therapeutic Target for Anxiety and Neurologic Disorders. European Archives of Psychiatry and Clinical Neuroscience, 262, S107-S12. [Google Scholar] [CrossRef] [PubMed]
[20] Poisbeau, P., Gazzo, G. and Calvel, L. (2018) Anxiolytics Targeting GABAA Receptors: Insights on Etifoxine. The World Journal of Biological Psychiatry, 19, S36-S45. [Google Scholar] [CrossRef] [PubMed]
[21] Li, X.-B., Liu, A., Yang, L., et al. (2018) Antidepressant-Like Effects of Translocator Protein (18 kDa) Ligand ZBD-2 in Mouse Models of Postpartum Depression. Molecular Brain, 11, 1-12. [Google Scholar] [CrossRef] [PubMed]
[22] Zhang, L.-M., Qiu, Z.-K., Zhao, N., et al. (2014) Anxiolytic-Like Effects of YL-IPA08, a Potent Ligand for the Translocator Protein (18 kDa) in Animal Models of Post-Traumatic Stress Disorder. International Journal of Neuropsychopharmacology, 17, 1659-1669. [Google Scholar] [CrossRef] 
[23] Luo, L.-F., Weng, J.-F., Cen, M., et al. (2019) Prognostic Significance of Serum Translocator Protein in Patients with Traumatic Brain Injury. Clinica Chimica Acta, 488, 25-30. [Google Scholar] [CrossRef] [PubMed]
[24] Palzur, E., Sharon, A., Shehadeh, M. and Soustiel, J.F. (2016) Investigation of the Mechanisms of Neuroprotection Mediated by Ro5-4864 in Brain Injury. Neuroscience, 329, 162-170. [Google Scholar] [CrossRef] [PubMed]
[25] Li, X.-M., Meng, J., Li, L.-T., et al. (2017) Effect of ZBD-2 on Chronic Pain, Depressive-Like Behaviors, and Recovery of Motor Function Following Spinal Cord Injury in Mice. Behavioural Brain Research, 30, 92-99. [Google Scholar] [CrossRef] [PubMed]
[26] Pigeon, H., Pérès, E.A., Truillet, C., et al. (2019) TSPO-PET and Diffusion-Weighted MRI for Imaging a Mouse Model of Infiltrative Human Glioma. Neuro-Oncology, 2, noz029. [Google Scholar] [CrossRef] [PubMed]
[27] Zeno, S., Zaaroor, M., Leschiner, S., Veenman, L. and Gavish, M. (2009) CoCl2 Induces Apoptosis via the 18 kDa Translocator Protein in U118MG Human Glioblastoma Cells. Biochemistry, 48, 4652-4661. [Google Scholar] [CrossRef] [PubMed]
[28] Daugherty, D.J., Selvaraj, V., Chechneva, O.V., et al. (2013) A TSPO Ligand Is Protective in a Mouse Model of Multiple Sclerosis. EMBO Molecular Medicine, 5, 891-903. [Google Scholar] [CrossRef] [PubMed]
[29] Abid, K.A., Sobowale, O.A., Parkes, L.M., et al. (2018) Assessing Inflammation in Acute Intracerebral Hemorrhage with PK11195 PET and Dynamic Contrast-Enhanced MRI. Journal of Neuroimaging, 28, 158-161. [Google Scholar] [CrossRef] [PubMed]